Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

Abstract Objective Sucroferric oxyhydroxide, a novel iron-based phosphate-binder, has been shown to have beneficial effects in lowering serum phosphorus levels and improving renal anemia in clinical studies. Although an effect of this agent on fibroblast growth factor 23 (FGF23) has been reported in...

Full description

Bibliographic Details
Main Authors: Hisato Shima, Keiko Miya, Kazuyoshi Okada, Jun Minakuchi, Shu Kawashima
Format: Article
Language:English
Published: BioMed Central 2018-06-01
Series:BMC Research Notes
Subjects:
CKD-MBD
Dialysis
FGF23
Iron-based phosphate binder
Renal anemia
Online Access:http://link.springer.com/article/10.1186/s13104-018-3483-6

Internet

http://link.springer.com/article/10.1186/s13104-018-3483-6

Similar Items